Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Hematologic Neoplasms × Cell Count × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Vulvar Neoplasms 1 Vulvar Diseases 1 Uterine Cervical Dysplasia 1 Sarcoma, Ewing 1 Sarcoma 1 Rhabdomyosarcoma 1 Rectal Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Papillomavirus Infections 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Leukemia, Myeloid, Acute 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Hodgkin Disease 1 Hematologic Neoplasms 1 Colonic Neoplasms 1 Carcinoma in Situ 1

Interventions

Cyclophosphamide 28 Tacrolimus 27 fludarabine 25 fludarabine phosphate 20 Mycophenolic Acid 19 Busulfan 18 Whole-Body Irradiation 17 Melphalan 14 Methotrexate 13 Rituximab 12 Antilymphocyte Serum 12 Bortezomib 10 Stem Cell Transplantation 9 Sirolimus 9 thymoglobulin 8 Peripheral Blood Stem Cell Transplantation 7 Granulocyte Colony-Stimulating Factor 7 Thiotepa 6 Cyclosporine 6 Clofarabine 6 Blood Specimen Collection 6 Alemtuzumab 6 merphos 5 Hematopoietic Stem Cell Transplantation 5 Filgrastim 5 Azacitidine 5 fedratinib 4 Voriconazole 4 Standard of Care 4 Nivolumab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01186809 2019-01-23

CIK2

A.O. Ospedale Papa Giovanni XXIII

Phase 2 Completed

74 enrolled 6 charts

Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡